tiprankstipranks
Revive Therapeutics Explores Bucillamine for Nerve Agents and Viral Threats
PremiumCompany AnnouncementsRevive Therapeutics Explores Bucillamine for Nerve Agents and Viral Threats
4M ago
Revive Therapeutics provides information update on Bucillamine and Mpox
Premium
The Fly
Revive Therapeutics provides information update on Bucillamine and Mpox
4M ago
Revive Therapeutics Tests Treatment for Nerve Agents
Premium
Company Announcements
Revive Therapeutics Tests Treatment for Nerve Agents
6M ago
Revive Therapeutics Advances Long COVID Treatment
PremiumCompany AnnouncementsRevive Therapeutics Advances Long COVID Treatment
8M ago
Revive Therapeutics granted Type C meeting request by FDA for bucillamine
Premium
The Fly
Revive Therapeutics granted Type C meeting request by FDA for bucillamine
8M ago
Revive Therapeutics Advances Long COVID Diagnostic
Premium
Company Announcements
Revive Therapeutics Advances Long COVID Diagnostic
8M ago
Revive Therapeutics submits Type C meeting request package to FDA
PremiumThe FlyRevive Therapeutics submits Type C meeting request package to FDA
9M ago
Revive Therapeutics Advances Bucillamine for Long COVID
Premium
Company Announcements
Revive Therapeutics Advances Bucillamine for Long COVID
9M ago
Revive Therapeutics to submit Type C meeting request with FDA for bucillamine
Premium
The Fly
Revive Therapeutics to submit Type C meeting request with FDA for bucillamine
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100